Central Sleep Apnea vs Obstructive Sleep Apnea: Key Differences, Causes, and Treatment

Sleep apnea is not a single condition. It's a category — and the two most common types, central sleep apnea and obstructive sleep apnea, are fundamentally different disorders with different causes, different physiological mechanisms, different treatment approaches, and critically, different responses to CPAP therapy. Getting the diagnosis right matters enormously, because treating the wrong type incorrectly can worsen outcomes.

As a licensed Registered Respiratory Therapist with ICU and critical care experience, I work with both types clinically. Here is the complete, accurate breakdown.

The Core Difference: Anatomy vs. Neurology

The fundamental distinction between the two types is where the problem originates:

Obstructive sleep apnea (OSA) is a mechanical problem. The airway physically collapses during sleep when upper airway muscle tone drops. The brain continues sending breathing signals — the respiratory drive is intact — but the effort cannot produce airflow because the airway is blocked. The patient is trying to breathe; they physically cannot.
Central sleep apnea (CSA) is a neurological problem. The airway is open and unobstructed, but the brain temporarily fails to send the signal to breathe. There is no obstruction — there is no effort. Breathing simply stops because the command to breathe is absent or inadequate.

This distinction — obstruction vs. absent respiratory drive — is what drives every difference in how these conditions present, how they're diagnosed, and how they're treated.

What Causes Each Type

Obstructive Sleep Apnea: Risk Factors and Causes

OSA is driven by anatomical and physiological factors that promote upper airway collapse during sleep:

Obesity — fat deposits around the pharynx narrow the airway and reduce its structural support
Upper airway anatomy — enlarged tonsils, large tongue base, retrognathia (recessed jaw), narrow hard palate
Reduced upper airway muscle tone during sleep — particularly during REM sleep when skeletal muscle tone is at its lowest
Supine sleep position — gravity pulls soft tissue posteriorly, narrowing the airway
Alcohol and sedatives — relax pharyngeal muscles and blunt arousal response
Male sex and postmenopausal status in women — hormonal factors affect airway muscle tone and fat distribution
Nasal obstruction — increases negative inspiratory pressure generated in the pharynx, promoting collapse

Central Sleep Apnea: Causes and Associated Conditions

CSA has several distinct etiological categories, each with different underlying mechanisms:

Heart failure with Cheyne-Stokes respiration — the most common cause of CSA in clinical practice. Reduced cardiac output causes delayed circulation time between the lungs and the chemoreceptors in the brainstem. The CO₂ signal that drives breathing oscillates — rising too high before triggering breathing, then overcorrecting and dropping too low, causing the breathing pause. The hallmark crescendo-decrescendo pattern of Cheyne-Stokes respiration reflects this oscillation.
Opioid-induced central apnea — opioids directly suppress the brainstem respiratory control centers, reducing or eliminating the CO₂ drive to breathe. Common in patients on chronic opioid therapy for pain management.
High altitude periodic breathing — at altitude, reduced oxygen triggers hyperventilation, which drops CO₂ below the apneic threshold, causing central apnea. Self-resolves with acclimatization.
Treatment-emergent central sleep apnea (complex sleep apnea) — central apneas that appear or increase after CPAP therapy for OSA. The positive pressure of CPAP eliminates obstructive events but unmasks or triggers central events that were previously hidden or caused by the pressure itself. Occurs in approximately 5–15% of OSA patients initiating CPAP.
Idiopathic central sleep apnea — no identifiable underlying cause; the brainstem respiratory control system is unstable at an intrinsic level without a secondary precipitant.
Neurological conditions — brainstem stroke, Parkinson's disease, multiple system atrophy, and other conditions affecting brainstem respiratory centers

How Each Appears on a Sleep Study

The definitive diagnostic distinction between OSA and CSA requires polysomnography — specifically, the respiratory effort channels. This is one of the key reasons an in-lab sleep study is necessary when CSA is suspected; home sleep tests cannot reliably differentiate the two.

Finding	Obstructive Apnea	Central Apnea
Airflow	Absent — airway blocked	Absent — no effort initiated
Respiratory effort (chest/abdominal bands)	Present — patient is trying to breathe	Absent — no breathing effort
Paradoxical chest/abdominal movement	Often present — effort against obstruction	Absent
Arousal pattern	Arousal at event termination from effort and hypoxia	Arousal may be absent or late
Oxygen desaturation	Yes — proportional to event duration and severity	Yes — may be gradual and cyclical
Cheyne-Stokes pattern	No	Yes — in heart failure related CSA

The respiratory effort channels are the key discriminator. Obstructive apneas show continued chest and abdominal movement — the patient is fighting against a blocked airway. Central apneas show flat effort channels — no movement at all because no signal is being sent.

Symptoms: Overlapping but Distinct

Both OSA and CSA disrupt sleep architecture and cause similar daytime symptoms: fatigue, excessive daytime sleepiness, cognitive impairment, morning headaches, and unrefreshing sleep. The symptom profiles overlap significantly, which is one reason clinical distinction requires objective testing rather than symptom assessment alone.

Features that may suggest CSA over OSA:

Known heart failure, particularly with reduced ejection fraction
Chronic opioid use for pain management
Witnessed apneas described as silent (no snoring, no gasping effort) rather than preceded by loud snoring and terminated by a gasp
Insomnia as a prominent feature alongside sleepiness — CSA patients sometimes experience more sleep initiation difficulty than classic OSA
Absence of the classic OSA risk factors (not obese, no large neck circumference, no anatomical upper airway abnormalities)

However, these are suggestive patterns, not diagnostic criteria. Definitive diagnosis requires sleep study.

Why CPAP Works for OSA but Can Worsen CSA

This is the most clinically critical distinction and the most common source of treatment error.

CPAP works for OSA by maintaining positive airway pressure that prevents the upper airway from collapsing. It addresses the mechanical obstruction directly and effectively. For straightforward OSA, CPAP is highly effective and appropriate first-line therapy.

For CSA, CPAP addresses a problem that isn't there — the airway is already open. More critically, the positive pressure of CPAP can actually worsen CSA in several ways:

CPAP washes out CO₂, lowering PaCO₂ below the apneic threshold and triggering more central apneas
CPAP suppresses obstructive events, unmasking pre-existing central events that were previously mixed or hidden within obstructive breathing patterns
In Cheyne-Stokes respiration from heart failure, CPAP may reduce venous return and affect cardiac output in ways that alter the CO₂ oscillation pattern

Placing a patient with pure central sleep apnea on standard CPAP can result in persistence or worsening of apnea events despite apparent therapy. This is why treatment-emergent central apnea — central events appearing after CPAP initiation in an OSA patient — requires clinical recognition and often a change in therapy approach.

Treatment Approaches for CSA

Treat the Underlying Cause First

For secondary CSA — CSA caused by heart failure, opioids, or neurological conditions — the primary intervention is optimizing treatment of the underlying condition:

Heart failure: Optimized guideline-directed medical therapy (ACE inhibitors/ARBs, beta-blockers, diuretics, SGLT2 inhibitors) reduces ventricular filling pressures and circulation time, which directly reduces the CO₂ oscillation driving Cheyne-Stokes respiration. Cardiac resynchronization therapy (CRT) in eligible patients also reduces CSA burden.
Opioid-induced CSA: Opioid dose reduction or rotation to a less respiratory-depressant agent where clinically feasible. Not always possible for patients with severe chronic pain.

ASV (Adaptive Servo-Ventilation)

ASV is the most sophisticated PAP therapy for CSA. It continuously analyzes the patient's breathing pattern and delivers targeted pressure support to stabilize ventilation — backing off when breathing is adequate, providing support when it's insufficient. It effectively prevents both the hyperventilation phase and the apnea phase of the Cheyne-Stokes cycle.

ASV is the treatment of choice for idiopathic CSA, treatment-emergent central apnea, and opioid-induced CSA. It is also effective for some heart failure patients with CSA.

Critical contraindication: ASV is contraindicated in patients with symptomatic heart failure with reduced ejection fraction (HFrEF, EF below 45%). The SERVE-HF trial demonstrated increased cardiovascular mortality with ASV in this specific population. This is an absolute contraindication, not a relative one. Every cardiac patient being considered for ASV requires ejection fraction assessment before therapy initiation.

Bilevel ST (BiPAP with Backup Rate)

BiPAP in spontaneous-timed (ST) mode delivers a mandatory breath at the set IPAP if the patient doesn't initiate a breath within the set time interval. This backup rate prevents prolonged central apneas by ensuring minimum ventilation. Less sophisticated than ASV in responding to breath-by-breath variability, but appropriate for some CSA presentations, particularly those with hypoventilation component.

Supplemental Oxygen

Low-flow supplemental oxygen can reduce central apnea burden in some CSA patients — particularly high-altitude CSA and idiopathic CSA — by raising baseline PaO₂ and reducing hypoxic ventilatory instability. Less effective than ASV for Cheyne-Stokes respiration but may be appropriate in specific clinical contexts.

Pharmacological Approaches

Acetazolamide — a carbonic anhydrase inhibitor that causes mild metabolic acidosis and stimulates breathing drive — is used for high-altitude CSA and has been studied in idiopathic CSA. Theophylline has also been used in some cases. These are second or third-line approaches used in specific clinical contexts under physician direction.

Treatment-Emergent Central Apnea: What to Do

If you started CPAP for OSA and your therapy data shows persistent elevated AHI with predominantly central events, here is the clinical pathway:

Confirm the pattern with your therapy data. OSCAR software or detailed AirView reports distinguish obstructive from central events. Your AHI on CPAP should show the breakdown by event type.
Allow time. Treatment-emergent central apnea often resolves spontaneously within 4–8 weeks of CPAP use as the respiratory control system adapts to the new pressure environment. Many patients who appear to have complex sleep apnea at CPAP initiation resolve to well-controlled OSA within 2 months.
If persistent at 8–12 weeks, seek clinical evaluation. Persistent treatment-emergent central apnea that doesn't resolve requires assessment for underlying causes (cardiac function, opioid use, neurological factors) and likely a transition to ASV.

Our $49.99 RT Consultation includes event-type analysis of your CPAP therapy data. If you're seeing unexpectedly high AHI on CPAP with events you can't explain, a licensed RRT can review your data, identify whether you're seeing central events, and guide the appropriate next steps.

Frequently Asked Questions

Can you have both central and obstructive sleep apnea at the same time?

Yes — this is called mixed or complex sleep apnea. Some patients have predominantly obstructive events with a minority of central events. Others have roughly equal proportions. The therapeutic approach depends on which type predominates and the underlying cause of the central component. Patients with significant mixed sleep apnea often require more sophisticated therapy than standard CPAP.

Is central sleep apnea more dangerous than obstructive?

Not inherently in terms of the apnea itself — both cause hypoxemia, sleep fragmentation, and cardiovascular stress. What makes CSA clinically significant is often the seriousness of its underlying cause. CSA from advanced heart failure carries the prognosis of the heart failure, not just the sleep apnea. CSA from opioids carries risks specific to that medication context. OSA, while highly prevalent and cardiovascular significant, is usually not a sign of a separate life-threatening condition in the way that Cheyne-Stokes CSA often is.

Will CPAP help if I have central sleep apnea?

Standard CPAP is generally not effective for pure CSA and can worsen it. If you have confirmed CSA, the appropriate therapy depends on the underlying cause — ASV for idiopathic or treatment-emergent CSA, BiPAP ST for CSA with hypoventilation, supplemental oxygen in specific contexts, and optimization of underlying conditions in secondary CSA. This requires physician evaluation and a new prescription — it cannot be managed by adjusting CPAP settings alone.

Can weight loss cure central sleep apnea the way it sometimes cures OSA?

No — weight loss addresses the anatomical factors driving OSA (airway fat deposition, chest wall load) but doesn't affect the neurological respiratory drive instability that causes CSA. For heart failure-related CSA, the relevant intervention is improving cardiac function, not weight loss per se (though weight loss may secondarily improve cardiac function in some patients).

How do I know if my CPAP is causing central apneas?

Check your therapy data. ResMed machines distinguish obstructive, central, hypopnea, and flow limitation events. In the myAir app, your AHI score is displayed but the detailed event breakdown requires the device's detailed report or OSCAR software. If your AHI is elevated on CPAP and you want a clinical interpretation of what event types are driving it, an RT consultation is the most direct path to that answer. See our full guide on understanding your CPAP AHI data.

The Bottom Line

Central sleep apnea and obstructive sleep apnea share a name and some symptoms but are mechanistically distinct conditions requiring different approaches. OSA is a mechanical airway problem treated effectively with CPAP or APAP. CSA is a neurological respiratory drive problem that requires identifying and treating the underlying cause, and often requires more sophisticated positive pressure therapy (ASV or BiPAP ST) rather than standard CPAP.

The clinical stakes of misidentifying the type are real: CPAP can worsen CSA, and the underlying cause of CSA (particularly heart failure) may require urgent management independent of sleep therapy. Get the right diagnosis from the right test, and make sure your treatment matches the type you actually have.

For a full overview of all PAP therapy device types and which conditions each treats, see our guide on CPAP, BiPAP, APAP, and ASV explained. For the foundational sleep apnea overview, see our article on sleep apnea symptoms, causes, and treatment. Browse our CPAP and BiPAP inventory or reach out for an $49.99 RT Consultation if your therapy data isn't making sense.

Written by Yashil Bhatt, RRT — Licensed Registered Respiratory Therapist with ICU and critical care experience and owner of My Respiratory Company.